https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38577 Wed 22 Mar 2023 17:23:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54589 Wed 15 May 2024 08:46:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13437 Wed 11 Apr 2018 09:28:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36862 Wed 07 Apr 2021 20:17:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43462 P<.001). Higher non-GI somatic symptom scores were significantly associated with both symptom transitions (odds ratio, 3.9; 95% CI, 1.38 to 10.77) and having sustained symptoms (odds ratio, 12.7; 95% CI, 4.62 to 34.90). Conclusion: The overall population prevalence of chronic unexplained GI symptoms is stable, but in individuals, transitions seem to be the rule. As these various GI syndromes appear to be so intimately interconnected, the common underlying pathogenesis may account for a major subgroup of chronic unexplained GI disorders.]]> Tue 20 Sep 2022 08:49:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50046 Thu 29 Jun 2023 14:52:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37534 Thu 04 Feb 2021 16:22:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13241 Sat 24 Mar 2018 08:17:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13237 Sat 24 Mar 2018 08:17:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11381 Sat 24 Mar 2018 08:11:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4993 A/3111-1G>A. Two cases had no gastrointestinal symptoms or signs of PA. PA is an inconstant feature of the subtype of epidermolysis bullosa known as JEB-PA. It is most likely that multiple factors influence the development of PA and its presence is not predictive of a poor outcome. It is possible that institutions that do not routinely screen immunofluorescence mapping for integrin α6β4 staining in the absence of PA are missing this form of epidermolysis bullosa.]]> Sat 24 Mar 2018 07:44:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25723 Sat 24 Mar 2018 07:33:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22209 Sat 24 Mar 2018 07:11:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48183 Sat 11 Mar 2023 12:23:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50595 Mon 31 Jul 2023 09:55:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49722 Mon 29 May 2023 15:20:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54035 Mon 29 Jan 2024 13:39:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50127 Mon 17 Jul 2023 11:12:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41856 18 years with lower GI hemorrhage requiring hospital admission from November 2011 to January 2014 were screened for trial eligibility (N = 265). INTERVENTIONS: A total of 100 patients were recruited after exclusions and were randomly assigned 1:1 to either tranexamic acid or placebo. MAIN OUTCOME MEASURES: The primary outcome was blood loss as determined by reduction in hemoglobin levels. The secondary outcomes were transfusion rates, transfusion volume, intervention rates for bleeding, length of hospital stay, readmission, and complication rates. RESULTS: There was no difference between groups with respect to hemoglobin drop (11 g/L of tranexamic acid vs 13 g/L of placebo; p = 0.9445). There was no difference with respect to transfusion rates (14/49 tranexamic acid vs 16/47 placebo; p = 0.661), mean transfusion volume (1.27 vs 1.93 units; p = 0.355), intervention rates (7/49 vs 13/47; p = 0.134), length of hospital stay (4.67 vs 4.74 d; p = 0.934), readmission, or complication rates. No complications occurred as a direct result of tranexamic acid use. LIMITATIONS: A larger multicenter trial may be required to determine whether there are more subtle advantages with tranexamic acid use in some of the secondary outcomes. CONCLUSIONS: Tranexamic acid does not appear to decrease blood loss or improve clinical outcomes in patients presenting with lower GI hemorrhage in the context of this trial. see Video Abstract at https://links.lww.com/DCR/A453.]]> Fri 12 Aug 2022 17:04:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36750 Fri 03 Jul 2020 09:05:42 AEST ]]>